Carbon Dioxide (CO2) Chemosensitivity and SUDEP

The Role of Central CO2 Chemosensitivity in Postictal Respiratory Depression and SUDEP

The purpose of this research study is to better understand what causes Sudden Unexpected Death in Epilepsy (SUDEP). This study will enroll subjects from the University of Iowa Hospitals and Clinics (UIHC) Epilepsy Monitoring Unit (EMU) and Epilepsy Clinics. The investigators will analyze the effects of seizures on breathing, on the cardiovascular system, and on arousal. The investigators are studying these effects because some cases of SUDEP might be due, in part, to an inability to wake up or sense elevated carbon dioxide (CO2) levels when breathing is impaired. Subjects will be followed for ten years after enrollment to monitor their health.

Study Overview

• Status: Recruiting
• Conditions: Epilepsy; SUDEP
• Intervention / Treatment: Other: 6% Carbon dioxide/50% oxygen/balance nitrogen mixture

Detailed Description

In this study, the investigators will only enroll adults with confirmed or suspected epilepsy; there is no control group. Patients admitted to the UIHC Epilepsy Monitoring Unit (EMU) for continuous VideoEEG will undergo video recordings of their face and body, electroencephalography (EEG), and electrocardiogram (ECG) as part of their normal clinical care. Research subjects will undergo noninvasive cardiorespiratory monitoring during their EMU stay for the purpose of correlating heart rate and breathing patterns with EEG patterns related to their seizures.

Eligible subjects will undergo several respiratory tests. This may include sniffing and breath holding and breathing through tubes of different sizes. One test, called the hypercapnic ventilatory response (HCVR), will have you rebreathe a gas mixture of 6% carbon dioxide and 50% oxygen to look at how more you breath in response to the increase in carbon dioxide levels. The investigators will then measure how much more subjects breathe in response to the increase in carbon dioxide levels, and also how breathing feels at the end of the test. The investigators will analyze the relationship between the HCVR and cardiorespiratory changes from seizures. The investigators will also analyze the effect of seizures on the HCVR. The HCVR test will be done by our respiratory therapist during subjects' stay in the EMU.

Some subjects will be asked to participate in repeat testing of the HCVR 3 more times as an outpatient over the next 2 years. Additional subjects will also be enrolled from the clinic and will also undergo HCVR testing 4 times over the 2 years. All subjects will agree to undergo an interview in person or by phone, email, or questionnaire annually for ten years. They will also provide consent for follow-up with a personal contact in the event of subject death, for the purpose of ascertaining whether the death was due to SUDEP.

• Study Type: Interventional
• Enrollment (Estimated): 335
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Study Coordinator; Phone Number: 319-356-4337; Email: dragond@healthcare.uiowa.edu

Study Locations

• United States
  • Iowa
    • Iowa City, Iowa, United States, 52242
      • Recruiting
      • University of Iowa Hospitals and Clinics
      • Contact: Brian K Gehlbach, MD; Phone Number: 319-356-3603; Email: brian-gehlbach@uiowa.edu
      • Principal Investigator: Brian Gehlbach, MD
      • Principal Investigator: George Richerson, MD, PhD
      • Contact: Deidre Dragon, BS; Phone Number: (319) 356-4337; Email: dragond@uiowa.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years to 95 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. The subject is between 18 and 99 years of age.
2. Confirmed or suspected epilepsy.
3. Admission to the EMU for spell characterization (EMU group) or undergoing care in the University of Iowa Health Care Epilepsy Clinic.

Exclusion Criteria:

1. History of uncontrolled cardiac, pulmonary, or hepatic disease.
2. Progressive or uncontrolled neurologic disease unrelated to epilepsy.
3. Current opioid use.
4. Women of child-bearing potential who are pregnant or capable of becoming pregnant (e.g. sexual activity within the past 21 days without a highly effective form of birth control or positive urine pregnancy test).
5. Other comorbid condition that may influence the safety or feasibility of HCVR testing.
6. Limited decision-making capacity and absence of a qualified representative.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Other: Respiratory physiology testing; Subjects will wear a nosepiece and breathe through a Y-valve that allows switching from room air to two 5-liter rebreathing bags pre-filled with 50% O2, 6% CO2, and balance N2. Ventilation and respiratory gases will be measured using a pneumotachograph and rapid gas analyzers (Ultima PFX pulmonary function/stress testing system, Medical Graphics Corp). In subjects who experience clinical seizure-like activity, we will repeat the HCVR. This repeat test will occur 2 or more hours after a generalized convulsive seizure (GCS). We will repeat the HCVR at least 30 minutes after a non-GCS. Finally, we may repeat the HCVR at least 18 hours after the last seizure (GCS or non-GCS). It is anticipated that some subjects may exhibit frequent seizures that necessitate the adjustment of this schedule. Subjects may also be asked to sniff, hold their breath, and breathe through tubes of different sizes.

Other: 6% Carbon dioxide/50% oxygen/balance nitrogen mixture; In the hypercapnic ventilatory response (HCVR) test, the subject will rebreathe a gas mixture that has 6% carbon dioxide and 50% oxygen. This test has been performed for decades for research and clinical purposes. The effects of carbon dioxide inhalation are short lived and do not cause long term consequences. the hypercapnic ventilatory response (HCVR), we will have you

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Determine the correlation between baseline central CO2 chemosensitivity and the increase in transcutaneous CO2 levels after a seizure.	The change in HCVR slope (change in minute ventilation [liters/min] vs change in end tidal CO2 [mm Hg]) will be correlated with the increase in transcutaneous CO2 level (mm Hg) provoked by a seizure.	Immediately before and after a seizure, variable for each subject but approximately 10 minutes
Determine the correlation between baseline central CO2 chemosensitivity and the duration of transcutaneous CO2 elevation above baseline after a seizure.	The change in HCVR slope (change in minute ventilation [liters/min] vs change in end tidal CO2 [mm Hg]) will be correlated with the duration (minutes) of end tidal CO2 elevation above pre-seizure baseline	Duration of hospital admission, approximately 5 days
Effect of seizures on HCVR slope (liters/min/mm Hg)	The percent change in HCVR slope (liters/min/mm Hg) from baseline that is induced by a seizure will be measured. The HCVR will be administered at 30 minutes, 2 hours, and 18 hours after nonconvulsive seizures. The HCVR will be administered at 2 hours and 18 hours after convulsive seizures.	Up to 18 hours after a seizure.
Determine the stability of the HCVR slope over time in patients with epilepsy. of the HCVR over time in patients with epilepsy	The stability of the HCVR slope (liters/min/mm Hg) measured 8 months for 2 years will be assessed using a generalized linear mixed model.	2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in respiratory rate provoked by seizures	Frequency of breaths (breaths/minute) will be measured using respiratory effort belts around the chest and abdomen	Immediately before and after a seizure, variable for each subject but approximately 10 minutes

Collaborators and Investigators

• Sponsor: University of Iowa
• Collaborators: National Institute of Neurological Disorders and Stroke (NINDS)
• Investigators: Principal Investigator: Brian Gehlbach, MD, University of Iowa; Principal Investigator: George Richerson, MD, PhD, University of Iowa

Study record dates

Study Major Dates

• Study Start (Actual): December 12, 2019
• Primary Completion (Estimated): October 1, 2029
• Study Completion (Estimated): October 1, 2029

Study Registration Dates

• First Submitted: October 8, 2019
• First Submitted That Met QC Criteria: October 18, 2019
• First Posted (Actual): October 22, 2019

Study Record Updates

• Last Update Posted (Actual): March 9, 2026
• Last Update Submitted That Met QC Criteria: March 5, 2026
• Last Verified: March 1, 2025

More Information

Terms related to this study

• Keywords: Epilepsy
• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Pathologic Processes; Death; Death, Sudden; Pathological Conditions, Signs and Symptoms; Sudden Unexpected Death in Epilepsy; Epilepsy
• Other Study ID Numbers: 201908728; 1R01NS113764-01 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Study data will be shared upon with qualified investigators upon completion of the study, under the guidelines of the NIH Data Sharing Policy and Implementation Guidance and under the control of the Principal Investigators.
• IPD Sharing Time Frame: Data elements will be potentially eligible for sharing 1 year after the study has been completed and the results have been disseminated via a summary report.
• IPD Sharing Access Criteria: Direct communication with the Principle Investigators.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No